US vs international Ozempic pricing. The same semaglutide pen lists 5–10× higher in America than in peer countries — but cheaper-abroad sourcing carries counterfeit and legal cautions, and US prices are set to change in 2027.
US list price versus peer nations and reported international retail. The Mexico figure is deliberately labeled reported — no neutral source publishes a precise price, so we don't state one as fact. Production cost is an estimate, not a sale price.
| Market | Price | Context | Source |
|---|---|---|---|
| United States (list) | ~$936/mo | ~$11,000/year list; net after rebates lower. Fully out of pocket for many without coverage. | KFF / Peterson-KFF |
| France | ~$83/mo | Same semaglutide pen, negotiated national price | KFF / Peterson-KFF |
| Japan | ~$169/mo | Same pen; US list runs 5–10× peer nations | KFF / Peterson-KFF |
| Mexico (retail, reported) | ~$200–370/mo | Reported retail range — not independently verified, no neutral published price | Reported / commercial (hedged) |
| Estimated production cost | ~$0.89–5/mo | Estimated profitable production cost — not a sale price | JAMA Network Open |
| US Medicare-negotiated (2027) | $274/mo | IRA-negotiated price effective 2027; Novo Nordisk also announced a $675/mo list cut | CMS (IRA) |
The price gap between the US and peer nations is real and large — 5× to 10× for the same pen. But the cheapest-looking route abroad is not automatically the safe or legal one, and the US picture changes in 2027. This is a cost comparison, not a recommendation to buy anywhere.
Ozempic lists near $936 a month in the US — about $11,000 a year — versus roughly $83 in France, $87 in Australia, and $169 in Japan for the same semaglutide pen, per KFF/Peterson data. That is a 5× to 10× difference for an identical product.
Mexican retail prices are reported in the ~$200–370/month range, well below the US list. These are reported commercial figures, not an independently verified or neutral published price, so they are treated as an estimate, not a fact. Other countries pay less mainly because their governments negotiate drug prices directly.
A peer-reviewed analysis in JAMA Network Open estimated that semaglutide could be manufactured at a profit for roughly $0.89 to $5 a month, with generic-scale production potentially $28–140 per person per year. That is the estimated production cost, not a market price.
There are two documented risks. Counterfeits: in June 2024 the WHO issued a global alert on falsified semaglutide, and the FDA has logged 455+ adverse-event reports tied to compounded copies. The law: FDA/CBP rules generally allow only up to a 90-day personal supply with a valid US prescription and original sealed product. This is information, not advice — talk to a licensed provider and pharmacist.
The landscape is shifting. Under the Inflation Reduction Act, Medicare's negotiated price for Ozempic lands around $274 a month in 2027, and Novo Nordisk has announced a US list-price cut to about $675/month effective January 2027. Whether an individual pays those figures still depends on insurance, coupons, and pharmacy.
Both are semaglutide, but Wegovy is the weight-loss-indicated brand and lists higher — around $1,349/month in the US. Pricing follows the brand and indication, not just the molecule, which is part of why US drug pricing is so hard to compare at face value.
The most striking honesty point in semaglutide pricing: a peer-reviewed JAMA Network Open analysis estimated the drug could be produced at a profit for a few dollars a month, yet the US list price runs near $936. Peer countries pay $83–$169 for the identical pen because their governments negotiate prices directly. The difference is policy and market structure, not the cost of the medicine.
Peer-nation list prices come from KFF/Peterson tracking. Mexico's retail figure, by contrast, is a reported commercial range (~$200–370/month) with no neutral published source, so we treat it as an estimate and not a fact. Anyone comparing prices should separate negotiated national list prices (well-documented) from reported retail or pharmacy figures (not independently verified).
Chasing a cheaper pen abroad or online carries two documented cautions. First, counterfeits: in June 2024 the WHO issued a global alert on falsified semaglutide, and the FDA has logged more than 455 adverse-event reports tied to compounded copies, including dosing errors. Second, the law: FDA and CBP rules generally permit only up to a 90-day personal supply, with a valid US prescription and original sealed product. This is information, not legal or medical advice.
Two changes are already scheduled. Under the Inflation Reduction Act, Medicare's negotiated price for Ozempic lands around $274/month in 2027, and Novo Nordisk has announced a US list cut to roughly $675/month effective January 2027. Whether any individual pays those numbers still depends on insurance, coupons, and pharmacy — but the headline list price most people quote today is not fixed.
Wellness Vision does not sell medication, book trips, or receive referrals. We do not recommend specific pharmacies, sellers, or providers, and we name none. The pricing data comes from KFF/Peterson, peer-reviewed JAMA research, CMS, the WHO, and the FDA. This is a cost comparison, not medical advice — talk to a qualified, licensed healthcare provider and pharmacist before any decision about medication.
Before you decide: a plain-English drug-pricing checklist (list vs net vs negotiated price, what changes in 2027, and the counterfeit and legal cautions worth knowing) — direct via newsletter, no Apple or Google fee.
📋 Or get the free Medical Travel Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
